This site is intended for health professionals only

Published on 22 November 2018

Share this story:
Twitter
LinkedIn

New drug could reduce risk of allergic reaction to peanuts in children and adolescents

A new oral biologic drug could reduce the risk of allergic reaction in children and adolescents following accidental peanut exposures, research has shown.

AR101 slowly builds up tolerance to peanut allergy, a study published in The New England Journal of Medicine found.

Researchers conducted PALISADE, a Phase 3 randomized, double-blind, placebo-controlled trial of oral immunotherapy (OIT) with AR101 in peanut-allergic patients aged 4 to 55 in Europe, the United States, and Canada.

Eligible subjects reacted at a challenge dose of 100mg or less of peanut protein (approximately one third of a peanut kernel) during a double-blind, placebo-controlled food challenge (DBPCFC) at screening.

The study looked at the proportion of participants aged four to 17 years of age who could ingest a challenge dose of 600 mg or more, without dose-limiting symptoms.

Study participants completed initial escalation and up-dosing phases, approximately six months of 300 mg per day maintenance treatment, and then an exit DBPCFC.

None of nearly 500 four to 17-year-olds taking part in the study could tolerate even a tenth of a peanut dose.

But after a year of taking small daily doses, 67% were able to ingest a dose of 600 mg or more of peanut protein, without dose-limiting symptoms, at the exit food challenge, researchers found.

However, no significant effect was found in participants 18 to 55 years of age.



Most read




Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Share this story:
Twitter
LinkedIn